219 related articles for article (PubMed ID: 12754350)
21. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients.
Simmons ML; Lamborn KR; Takahashi M; Chen P; Israel MA; Berger MS; Godfrey T; Nigro J; Prados M; Chang S; Barker FG; Aldape K
Cancer Res; 2001 Feb; 61(3):1122-8. PubMed ID: 11221842
[TBL] [Abstract][Full Text] [Related]
22. Molecular genetic changes in a series of neuroepithelial tumors of childhood.
Di Sapio A; Morra I; Pradotto L; Guido M; Schiffer D; Mauro A
J Neurooncol; 2002 Sep; 59(2):117-22. PubMed ID: 12241104
[TBL] [Abstract][Full Text] [Related]
23. Creutzfeldt astrocytes may be seen in IDH-wildtype glioblastoma and retain expression of DNA repair and chromatin binding proteins.
Ballester LY; Boghani Z; Baskin DS; Britz GW; Olsen R; Fuller GN; Powell SZ; Cykowski MD
Brain Pathol; 2018 Nov; 28(6):1012-1019. PubMed ID: 29509313
[TBL] [Abstract][Full Text] [Related]
24. Msh2, Mlh1, Fhit, p53, Bcl-2, and Bax expression in invasive and in situ squamous cell carcinoma of the uterine cervix.
Giarnieri E; Mancini R; Pisani T; Alderisio M; Vecchione A
Clin Cancer Res; 2000 Sep; 6(9):3600-6. PubMed ID: 10999751
[TBL] [Abstract][Full Text] [Related]
25. The role of a single nucleotide polymorphism of MDM2 in glioblastoma multiforme.
Khatri RG; Navaratne K; Weil RJ
J Neurosurg; 2008 Nov; 109(5):842-8. PubMed ID: 18976073
[TBL] [Abstract][Full Text] [Related]
26. Discovery of a perinecrotic 60 kDa MDM2 isoform within glioma spheroids and glioblastoma biopsy material.
Bell HS; Whittle IR; Bader SA; Wharton SB
Neuropathol Appl Neurobiol; 2005 Apr; 31(2):191-202. PubMed ID: 15771712
[TBL] [Abstract][Full Text] [Related]
27. [Clinical and pathological significance of p53 gene mutation in human cerebral glioblastoma multiforme].
Matsumoto R
Hokkaido Igaku Zasshi; 1998 Jul; 73(4):407-17. PubMed ID: 9828926
[TBL] [Abstract][Full Text] [Related]
28. EGFR overexpression and radiation response in glioblastoma multiforme.
Barker FG; Simmons ML; Chang SM; Prados MD; Larson DA; Sneed PK; Wara WM; Berger MS; Chen P; Israel MA; Aldape KD
Int J Radiat Oncol Biol Phys; 2001 Oct; 51(2):410-8. PubMed ID: 11567815
[TBL] [Abstract][Full Text] [Related]
29. Molecular analysis of p53, MDM2, and H-ras genes in osteosarcoma and malignant fibrous histiocytoma of bone in patients older than 40 years.
Kawaguchi K; Oda Y; Sakamoto A; Saito T; Tamiya S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2002 Aug; 15(8):878-88. PubMed ID: 12181274
[TBL] [Abstract][Full Text] [Related]
30. Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors.
Lang FF; Miller DC; Koslow M; Newcomb EW
J Neurosurg; 1994 Sep; 81(3):427-36. PubMed ID: 8057151
[TBL] [Abstract][Full Text] [Related]
31. Primary and secondary glioblastomas: from concept to clinical diagnosis.
Kleihues P; Ohgaki H
Neuro Oncol; 1999 Jan; 1(1):44-51. PubMed ID: 11550301
[TBL] [Abstract][Full Text] [Related]
32. Manganese superoxide dismutase (MnSOD) is a malignant astrocytoma specific biomarker and associated with adverse prognosis in p53 expressing glioblastoma.
Shwetha SD; Shastry AH; Arivazhagan A; Santosh V
Pathol Res Pract; 2016 Jan; 212(1):17-23. PubMed ID: 26616112
[TBL] [Abstract][Full Text] [Related]
33. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
34. Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration.
Ruano Y; Ribalta T; de Lope AR; Campos-Martín Y; Fiaño C; Pérez-Magán E; Hernández-Moneo JL; Mollejo M; Meléndez B
Am J Clin Pathol; 2009 Feb; 131(2):257-63. PubMed ID: 19141386
[TBL] [Abstract][Full Text] [Related]
35. A comparative study of epidermal growth factor receptor (EGFR) and MDM2 gene amplification and protein immunoreactivity in human glioblastomas.
Rieske P; Kordek R; Bartkowiak J; Debiec-Rychter M; Biernat W; Liberski PP
Pol J Pathol; 1998; 49(3):145-9. PubMed ID: 9810172
[TBL] [Abstract][Full Text] [Related]
36. p53 mutations versus EGF receptor expression in giant cell glioblastomas.
Peraud A; Watanabe K; Plate KH; Yonekawa Y; Kleihues P; Ohgaki H
J Neuropathol Exp Neurol; 1997 Nov; 56(11):1236-41. PubMed ID: 9370234
[TBL] [Abstract][Full Text] [Related]
37. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
[TBL] [Abstract][Full Text] [Related]
38. p53 and MDM2 in the development and progression of bladder cancer.
Schmitz-Dräger BJ; Kushima M; Goebell P; Jax TW; Gerharz CD; Bültel H; Schulz WA; Ebert T; Ackermann R
Eur Urol; 1997; 32(4):487-93. PubMed ID: 9412812
[TBL] [Abstract][Full Text] [Related]
39. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities.
Ichimura K; Bolin MB; Goike HM; Schmidt EE; Moshref A; Collins VP
Cancer Res; 2000 Jan; 60(2):417-24. PubMed ID: 10667596
[TBL] [Abstract][Full Text] [Related]
40. No association of MDM2 SNP309 with risk of glioblastoma and prognosis.
El Hallani S; Marie Y; Idbaih A; Rodero M; Boisselier B; Laigle-Donadey F; Ducray F; Delattre JY; Sanson M
J Neurooncol; 2007 Dec; 85(3):241-4. PubMed ID: 17568997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
